Veracyte Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Veracyte (VCYT) Tops Q2 EPS by 9c, Revenues Beat; Boosts FY18 Revenue Guidance
July 23, 2018 4:11 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $20.56 million.
We delivered another exceptional quarter of revenue and genomic test volume growth, said Bonnie Anderson, chairman and chief executive officer of Veracyte. We saw strong growth in our Afirma business where our deep... More
